NICE recommends remote monitoring technology for heart failure patients
Heart failure accounted for approximately 90,000 hospital admissions in England in 2019 to 2020
Read More
Tag: National Institute for Health and Care Excellence
NICE recommends Santen’s Roclanda to treat glaucoma and ocular hypertension
Primary open-angle glaucoma affects around 2% of adults aged 40 years and older in the UK
Read More
NHS and NICE announce plan to adopt innovative medical technologies for patients
The proposals will help MedTech developers access NHS funding to fast-track products
Read More
NIHR awards over £20m to eight new global health research projects
The projects will focus on healthcare in LMICs in the event of extreme weather
Read More
Wearable technology to be offered to thousands with type 1 diabetes in UK
The condition affects around 270,935 people in England and 16,090 people in Wales
Read More
NICE publishes draft cerebral palsy quality standard
The draft standard consists of five statements, which together highlight what needs to be done to ensure adults with cerebral palsy can be “as independent as possible and have equal access to every available opportunity.”
Read More
NICE to work with GW Pharma after Epidiolex rejection
The committee also cited concerns about the economic models provided by the company.
Read More
Skyrizi bags NICE fast-track
Eligible patients in England and Wales will have access to the drug almost two months earlier.
Read More
Research supports better integration of patient voice in health technology assessments
The research will help ensure new treatments reflect the needs and preferences of patients and family members living with myeloma and other conditions.
Read More
Ocrevus finally available on NHS
The availability of Ocrevus has been branded a “landmark moment” by the MS Society.
Read More
New NICE guidelines on antibiotic prescribing for pneumonia
The National Institute for Health and Care Excellence (NICE) and Public Health England (PHE) have published draft guidance on antimicrobial prescribing for hospital-acquired and community-acquired pneumonia, setting out a strategy designed to optimise antibiotic use and reduce antibiotic resistance.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
